Farma

pips
30.04.2019 kl 08:23 4047

NattoPharma with strong growth in the first quarter
Oslo, Norway (30 April 2019)

NattoPharma increased revenues by 41% in the first quarter and delivered a
positive adjusted EBITDA of NOK 1,9 million.

"We are pleased to deliver a strong first quarter. We continue to demonstrate
our ambition of profitable growth which is a result of the increased focus in
the organization in the last two to three years.

In the quarter we continued our investments in future growth and profitability
with the synthetic K2 development project, where we anticipate initial results
during Q2. We also see increasing demand in the market and are working
relentlessly to capture a part of this growth through sales and marketing
efforts and product offerings. We believe we are on track to deliver in the
upper parts of previous guiding with an annual revenue growth of 30-35% and
gross margins of 40-45%"

Financial highlights:

+----------------+------+------+-----------+------+
/(mnok) /Q1'19 /Q1'18 /Change /2018 /
+----------------+------+------+-----------+------+
/Product Revenue /27,8 /19,8 /8,0 (+41%) /101,7 /
+----------------+------+------+-----------+------+
/Gross Margin /44,1% /41,3% /+2,7% /43,1% /
+----------------+------+------+-----------+------+
/EBITDA (adj.) /1,9 /0,4 /1,5 /6,7 /
+----------------+------+------+-----------+------+
/EBT /-0,4 /-3,5 /3,1 /1,8 /
+----------------+------+------+-----------+------+

Please find enclosed the Nattopharma Group First Quarter 2019 Report.

For more information, please contact:

Kjetil Ramsøy

CEO, NattoPharma
Redigert 30.04.2019 kl 08:24

Rapportér innlegg

Vennligst skriv inn kommentar på hva du mener er upassende og trykk send. Dersom kommentar ikke er nødvendig, vennligst trykk send direkte.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.